About this trial

This multicenter retrospective observational cohort study seeks to:

1. Classify surgical intent in patients with resected Intraductal Papillary Mucinous Neoplasms (IPMN) and quantify the proportion of IPMN-associated cancers diagnosed as overt pancreatic cancer with incidental IPMN association on pathology. 2. Compare clinicopathologic features and outcomes between surveillance-detected and incidentally detected IPMN-derived pancreatic cancers. 3. Revise and redefine risk features limited to patients undergoing surgery for IPMN-related indications, identifying optimal predictors of malignant IPMN (high-grade dysplasia or invasive cancer).

Eligibility criteria

Qualifiers

All patients (18 years old of greater) who underwent surgical resection for IPMN (including low-, high-grade dysplasia, or invasive carcinoma) between July 1, 2015 and July 1, 2025.

Disqualifiers

Patients with concomitant pancreatic ductal adenocarcinoma (PDAC)

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

2,000 Participants
are grouped into 1 trial group

Locations

14
China
Nanjing University210093, Nanjing China
Germany
Heidelberg University69117, Heidelberg Germany
Italy
San Raffaele Hospital20132, Milan Italy
Padua University1222, Padua Italy

Sponsors and collaborators

NYU Langone Health

Lead sponsor